The rate of recurrence of ascites after surgical treatment in patients in whom fistulae could not be demonstrated is high. These issues support our decision to proceed with endoscopic therapy in ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...